Bagel J, Armstrong AW, Warren RB, Papp KA, Thaçi D, Menter A, Cather J, Augustin M, Hippeli L, Daamen C, Griffiths CE. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 4];7(2):s117. Available from: https://jofskin.org/33014/index.php/skin/article/view/1969